Mutational exclusivity between KRAS and B-RAF mutations can cause variations in the immune response to tumours, with KRAS-mutant tumours exhibiting a lower rate of immune cell infiltration compared to WT, whereas B-RAF mutations caused an increase in immune cell infiltration, compared to WT (Edin et al., 2024). The gene discussed is BRAF; the disease is neoplasm.